Shanghai Junshi Biosciences Co Ltd (SHG:688180) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Junshi Biosciences Co Ltd (688180)
Shanghai Junshi Biosciences Co Ltd (SHG:688180) has a market capitalization of $4.09 Billion (CN¥27.95 Billion) as of August 1, 2026. Listed on the SHG stock exchange, this China-based company holds position #4009 globally and #583 in its home market, demonstrating a -1.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Junshi Biosciences Co Ltd's stock price CN¥36.51 by its total outstanding shares 765578300 (765.58 Million). See Shanghai Junshi Biosciences Co Ltd (688180) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
Shanghai Junshi Biosciences Co Ltd Market Cap History: 2020 to 2026
Shanghai Junshi Biosciences Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $9.09 Billion to $4.09 Billion (-20.93% CAGR).
Shanghai Junshi Biosciences Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Junshi Biosciences Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.53x
Shanghai Junshi Biosciences Co Ltd's market cap is 1.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $9.09 Billion | $1.59 Billion | -$1.67 Billion | 5.70x | N/A |
| 2021 | $7.50 Billion | $4.02 Billion | -$720.91 Million | 1.86x | N/A |
| 2022 | $7.01 Billion | $1.45 Billion | -$2.39 Billion | 4.82x | N/A |
| 2023 | $4.69 Billion | $1.50 Billion | -$2.28 Billion | 3.12x | N/A |
| 2024 | $3.06 Billion | $1.95 Billion | -$1.28 Billion | 1.57x | N/A |
| 2025 | $3.83 Billion | $2.50 Billion | -$875.17 Million | 1.53x | N/A |
Competitor Companies of 688180 by Market Capitalization
Companies near Shanghai Junshi Biosciences Co Ltd in the global market cap rankings as of August 1, 2026.
Key companies related to Shanghai Junshi Biosciences Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Shanghai Junshi Biosciences Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Shanghai Junshi Biosciences Co Ltd's market cap moved from $9.09 Billion to $ 4.09 Billion, with a yearly change of -20.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥4.09 Billion | +6.88% |
| 2025 | CN¥3.83 Billion | +24.99% |
| 2024 | CN¥3.06 Billion | -34.66% |
| 2023 | CN¥4.69 Billion | -33.18% |
| 2022 | CN¥7.01 Billion | -6.54% |
| 2021 | CN¥7.50 Billion | -17.41% |
| 2020 | CN¥9.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Shanghai Junshi Biosciences Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.09 Billion USD |
| MoneyControl | $4.09 Billion USD |
| MarketWatch | $4.09 Billion USD |
| marketcap.company | $4.09 Billion USD |
| Reuters | $4.09 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Junshi Biosciences Co Ltd
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more